Fibrodysplasia
ossificans progressiva (FOP), also known as myositis ossificans progressive, is a rare
inherited connective tissue disorder characterized by abnormal bone development
in ligaments, tendons, and skeletal muscles.
Precisely,
FOP causes the body's skeletal muscles and soft connective tissues to undergo a
metamorphosis, transforming into bone, gradually locking joints and making
movement difficult. FOP is inherited as an autosomal dominant trait with
complete penetrance. Standard therapies available for FOP are; corticosteroids
and non-steroidal anti-inflammatory medication for pain and swelling associated
with FOP; occupational therapy; and genetic counselling.
Request
to Get Free Sample Pages at:
Regeneron
Pharmaceuticals Inc. is in the process of developing REGN2477 as an activin A
antibody which act as an activin modulator for the treatment of FOP. Some of
the companies in FOP pipeline are Clementia Pharmaceuticals Inc. and Regeneron
Pharmaceuticals Inc. among others.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment